<DOC>
	<DOCNO>NCT00244686</DOCNO>
	<brief_summary>104317 : The market authorisation application mepolizumab indication hypereosinophilic syndrome ( HES ) file 2008 , later file withdrawn due outstanding question regulator 's raise application . On basis sponsor 's evaluation , participant life-threatening HES document failure ( lack efficacy contra-indication ) least 3 standard HES therapy ( compassionate use ) participant participate previous GSK sponsor study HES ( long-term access ) consider mepolizumab treatment country regulation permit . In study , participant receive mepolizumab open-labelled manner , limited data collect evaluate long-term safety efficacy mepolizumab . 201956 : This Long-term Access Programme ( LAP ) aim support provision mepolizumab , commercially available , eligible subject severe asthma participate GSK-sponsored mepolizumab clinical study severe asthma . Eligible subject initiate mepolizumab within 6-month period follow individual subject 's last scheduled visit precede clinical study . For subject benefit versus risk assess throughout study support continue treatment mepolizumab .</brief_summary>
	<brief_title>This Record Contains Information About Mepolizumab Compassionate Use Product Activities : 104317 : An Open-Label Compassionate Use Long-Term Access Study Mepolizumab HES 201956 : A Long-term Access Programme Subjects With Severe Asthma</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<criteria>104317 Inclusion criterion : â‰¥ 12 year age Has lifethreatening HES define treat physician 's documented view likelihood death high unless course disease interrupt . Meets diagnostic criterion Hyper Eosinophilic Syndrome define : Eosinophilia &gt; 1500cells/ul least 6 month evidence symptom sign organ system involvement dysfunction directly relate eosinophilia ( evidence parasitic , allergic recognize cause eosinophilia connective tissue disease , malignancy ) Eosinophilia &gt; 1500cells/ul le 6 month meet criterion HES accompany clear evidence eosinophil tissue infiltration exclusion secondary cause eosinophilia . Compassionate use : Documented failure ( lack efficacy contraindication ) least 3 standard therapy ( corticosteroid , cytotoxic agent , immunomodulatory therapy , Imatinib mesylate ) appropriate duration dose Longterm access : Entry subject participate previous GSK HES study study must support following : Subjects receive mepolizumab ( study treatment know ) previous GSK HES study : Documented improvement symptom and/or sign HES follow treatment mepolizumab Subjects receive mepolizumab placebo previous GSK HES study : The treat physician must confirm positive benefit/risk ratio , anticipated clinical benefit mepolizumab must outweigh potential safety tolerability risk study Subjects participate Study 200622 complete protocol require assessment duration 32 week randomization . Subsequently , subject complete 20week assessment Study 205203 , openlabel extension ( OLE ) Study 200622 , prior consider protocol ( MHE104317 ) . In addition , subject adverse event ( serious nonserious ) consider related study treatment participate Study 200622 Study 205203 result permanent withdrawal study treatment . 104317 Subjects without HES condition associate eosinophilic pathological process ChurgStrauss , Wegner 's Granulomatosis , atopic disorder , hypersensitivity reaction parasitic infection , eosinophilic gastroenteropathies , eligible compassionate use program restrict lifethreatening HES . Female subject child bear potential use effective method contraception : Consistent correct use one follow acceptable method birth control one month prior start investigation product 16 week last dose . Pregnant lactate female Subjects severe/lifethreatening underlying disease unrelated HES unrelated HES life expectancy estimate less 3 month . Subjects history current malignancy : Subjects history current lymphoma Subjects current malignancy previous history cancer remission le 12 month prior first dose . Subjects localize carcinoma ( i.e. , basal squamous cell ) skin resect cure exclude . Subjects history serious allergic reaction ( hypersensitivity/anaphylaxis ) antiIL5 antibody therapy know suspected hypersensitivity component mepolizumab , lead treatment discontinuation Subjects current drug alcohol abuse uncertain compliance medication cause safety risk . subject currently receive investigational product investigational intervention . 201956 Inclusion criterion : Subject participate GSKsponsored asthma clinical study mepolizumab . Subject either : complete treatment period mepolizumab asthma clinical study originally enrol subject withdrawn study treatment prematurely mepolizumab asthma clinical study originally enrol subject complete study assessment study visit would end respective treatment period . The treat physician request mepolizumab Longterm Access Programme consider benefit treatment mepolizumab outweigh risk individual subject . To eligible mepolizumab treatment Longterm Access Programme , females childbearing potential ( FCBP ) must commit consistent correct use acceptable method birth control , begin consent , duration treatment mepolizumab 4 month last mepolizumab administration . The subject consent receive treatment mepolizumab Longterm Access Programme . In case paediatric subject eligible parent ( ) /guardian give write informed consent prior child 's participation study . If applicable , subject must able willing give assent take part study accord local requirement . 201956 Exclusion criterion : A current malignancy history cancer remission le 12 month ( Subjects localize carcinoma ( i.e. , basal squamous cell ) skin resect cure exclude ) . Subject clinically significant medical condition uncontrolled standardofcare therapy associate asthma , e.g. , unstable liver disease , uncontrolled cardiovascular disease , ongoing active infectious disease require systemic treatment . Subject pregnant breastfeeding . Subjects consider continue treatment plan become pregnant course treatment mepolizumab . Subject know allergy intolerance monoclonal antibody biologic therapy include mepolizumab . Subject adverse event ( serious nonserious ) consider related study treatment whilst participate clinical study mepolizumab result permanent withdrawal study treatment . Subject receive treatment another biological therapy monoclonal antibody therapy intravenous ( IV ) immunoglobulin ( Ig ) therapy . Subjects receive treatment investigational drug within past 30 day 5 terminal phase halflives drug whichever longer , prior initiation mepolizumab treatment Longterm Access Programme ( also include investigational formulation market product ) . Subject currently participate interventional clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Hypereosinophilic Syndrome</keyword>
	<keyword>Mepo</keyword>
	<keyword>HES</keyword>
	<keyword>Compassionate Use</keyword>
	<keyword>Mepolizumab</keyword>
</DOC>